yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
Cloud Expo & Virtualization 2009 East
Smarter Business Solutions Through Dynamic Infrastructure
Smarter Insights: How the CIO Becomes a Hero Again
Windows Azure
Why VDI?
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun's Incubation Platform: Helping Startups Serve the Enterprise
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
Apogenix's Apocept™ for Glioblastoma Multiforme Named One of "Top 10 Projects to Watch"

HEIDELBERG, Germany, Nov. 6, 2012 /PRNewswire/ -- Apogenix, a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases, today announced that its lead product, Apocept™ (APG101), has been selected by Elsevier Business Intelligence and Windhover Conferences as one of oncology's "Top 10 Projects To Watch." This announcement is in conjunction with the "Therapeutic Area Partnerships" conference event taking place in Boston from Nov. 28 to 30. Apogenix's CEO, Thomas Hoeger, Ph.D., will be presenting an overview on Apogenix's controlled Phase 2 study of Apocept in patients with recurrent glioblastoma multiforme (GBM) on Nov. 29.

"We are honored that our lead candidate, Apocept, has been selected as one of Windhover's Top 10 Projects to Watch," said Dr. Hoeger. "Apocept is the first drug in more than a decade that has shown clear benefits in a randomized, controlled clinical trial regarding quality of life, progression free survival as well as overall survival in patients with recurrent GBM, a disease that represents a tremendous unmet medical need. Best responses were seen in patients expressing a newly identified biomarker. Apocept's unique mechanism of action has potential in many other cancers beyond GBM."

"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees considered the most attractive oncology opportunities the industry has to offer," said David Cassak, Vice President, Content, Windhover Conferences, a division of Elsevier Business Intelligence. "Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability."

About Apogenix
Apogenix, a spin-out from the German Cancer Research Center (DKFZ), is developing novel protein therapeutics for the treatment of cancer and inflammatory diseases based either on the targeted modulation of apoptosis (programmed cell death) or on blocking the growth of tumour cells. The company's lead product candidate Apocept (APG101) is being developed for the treatment of glioblastoma, the most common and aggressive type of primary brain tumour. In 2013, an additional clinical study with Apocept will be initiated in patients suffering from myelodysplastic syndromes. Since its inception in 2005, the company has raised more than €50 million with dievini Hopp BioTech Holding GmbH & Co. KG as main investor, and has been awarded public grants totaling over € 8 million. Apogenix is based in Heidelberg, Germany.

About Apocept (APG101)
The company's lead product candidate, Apocept, a first-in-class, fully human fusion protein combining the extracellular domain of the CD95 receptor and the Fc portion of IgG, successfully completed a phase 1 study in 2009. In December 2009, Apogenix started a controlled phase 2 trial with the compound for the treatment of recurrent glioblastoma. The patient recruitment for this study was completed in September 2011. The primary endpoint as well as a number of secondary endpoints of the trial were successfully reached in 2012. Apogenix was granted orphan drug designation for Apocept in 2009 for the treatment of glioblastoma in Europe and in the US.

About Glioblastoma
Glioblastoma is the most frequent and aggressive brain tumour belonging to the group of gliomas. The tumour cells show a high resistance to radiation and chemotherapy. They spread and infiltrate the neighboring tissue so quickly that eradicative surgery is often impossible. Due to the diffuse infiltration into brain tissue, recurrence is often experienced within months after initial treatment. Approximately 28,000 new cases of malignant glioma are diagnosed in the US and EU each year (Source: US National Cancer Registry). The current standard therapy focuses on surgery, followed by radiotherapy and chemotherapy. The relative survival rate for adults diagnosed with glioblastoma is less than 30% within one year of diagnosis. Only 3% of patients live longer than five years after primary diagnosis (Source: Central Brain Tumor Registry of the United States) showing the high unmet medical need in this indication. Currently, there are no approved treatment options available for recurrent glioblastoma patients with proven efficacy data from an actively controlled clinical trial.


Dr. Thomas Hoeger


Apogenix GmbH

D-69120 Heidelberg, Germany

Phone: +49 (6221) 5 86 08-0


Media Contacts                              



Martina Schwarzkopf, Ph.D.

Raimund Gabriel

Russo Partners

MC Services AG 

Phone: + 1 (212) 845 4292

Phone: +49 (89) 210 228 30

SOURCE Apogenix

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Cloud Developer Stories
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the C...
In his General Session at 17th Cloud Expo, Bruce Swann, Senior Product Marketing Manager for Adobe Campaign, explored the key ingredients of cross-channel marketing in a digital world. Learn how the Adobe Marketing Cloud can help marketers embrace opportunities for personalized...
The buzz continues for cloud, data analytics and the Internet of Things (IoT) and their collective impact across all industries. But a new conversation is emerging - how do companies use industry disruption and technology enablers to lead in markets undergoing change, uncertainty...
Countless business models have spawned from the IaaS industry – resell Web hosting, blogs, public cloud, and on and on. With the overwhelming amount of tools available to us, it's sometimes easy to overlook that many of them are just new skins of resources we've had for a long ti...
In recent years, at least 40% of companies using cloud applications have experienced data loss. One of the best prevention against cloud data loss is backing up your cloud data. In his General Session at 17th Cloud Expo, Sam McIntyre, Partner Enablement Specialist at eFolder, p...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)!

Advertise on this site! Contact advertising(at)! 201 802-3021

SYS-CON Featured Whitepapers